Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: A study from a south Indian perspective

Pharmacogenomics

Volumn 13, Issue 10, 2012, Pages 1119-1127

  Vijayan, Neetha N ^a   Mathew, Anila ^a   Balan, Shabeesh ^a   Natarajan, Chandrasekhar ^a   Nair, Chandrashekharan M ^b   Allencherry, Priya M ^c   Banerjee, Moinak ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

^b Nair's Hospital   (India)

^c Mental Health Centre   (India)

Author keywords

ABCB1; antipsychotics; BPRS rating; chlorpromazine; dosing; pharmacogenomics; polytherapy; refractory; schizophrenia; south India

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CASE CONTROL STUDY; CONTROLLED STUDY; DIZZINESS; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE PROTEIN 1 GENE; PHARMACOGENOMICS; PHENOTYPE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CASE-CONTROL STUDIES; CHLORPROMAZINE; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; MALE; MIDDLE AGED; P-GLYCOPROTEIN; SCHIZOPHRENIA;

EID: 84865341189     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.86     Document Type: Article

References (44)

1. Kinon BJ, Chen L, Ascher-Svanum H et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr. Res. 102(1-3), 230-240 (2008).
2. Ascher-Svanum H, Nyhius AW, Faris DE, Kinon BJ, Baker RW, Shekar A. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr. Bull. 34(6), 1163-1171 (2008).
3. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr. Res. 28(2-3), 199-206 (1997). (Pubitemid 28055667)
4. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr. Serv. 54(4), 508-516 (2003). (Pubitemid 36752981)
5. Kerwin RW, Arranz MJ. Psychopharmacogenetics. In: Psychiatric Genetics and Genomics. McGuffin P, Owen MJ, Gottesman II (Eds). Oxford University Press, UK, 397-414 (2002).
6. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am. J. Psychiatr. 161(5), 780-796 (2004). (Pubitemid 38625331)
7. Bebawy M, Chetty M. Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. Bioessays 30(2), 183-188 (2008). (Pubitemid 351196953)
8. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 71(2), 163-169 (2002). (Pubitemid 34595435)
9. Maines LW, Antonetti DA, Wolpert EB, Smith CD. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49(5), 610-617 (2005). (Pubitemid 41208282)
10. Moons T, de Roo M, Claes S, Dom G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 12(8), 1193-1211 (2011).
11. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatr. 23(2), 103-111 (2010).
12. Sharom FJ. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 160(3), 161-175 (1997). (Pubitemid 28026729)
13. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97(11), 2517-2524 (1996). (Pubitemid 26187339)
14. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26(2), 180-185 (2004). (Pubitemid 38501215)
15. Mickley LA, Lee JS, Weng Z et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91(5), 1749-1756 (1998). (Pubitemid 28110341)
16. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000). (Pubitemid 30183327)
17. Thomas R, Nair SB, Banerjee M. A crypto-Dravidian origin for the nontribal communities of south India based on human leukocyte antigen class I diversity. Tissue Antigens 68(3), 225-234 (2006). (Pubitemid 44341796)
18. Vijayan NN, Bhaskaran S, Koshy LV et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a south Indian population. Behav. Brain Funct. 3, 34 (2007).
19. Dingemans PM, Linszen DH, Lenior ME, Smeets RM. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacol. (Berl.) 122, 263-267 (1995).
20. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64(6), 663-667 (2003). (Pubitemid 36750143)
21. Lachar D, Bailley SE, Rhoades HM, Varner RV. Use of BPRS-A percent change scores to identify significant clinical improvement: accuracy of treatment response classification in acute psychiatric inpatients. Psychiatr. Res. 89(3), 259-268 (1999). (Pubitemid 30053008)
22. Vahab SA, Sen S, Ravindran N et al. Analysis of genotype and haplotype effects of ABCB1 (MDR1) polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab. Pharmacokinet. 24(3), 255-260 (2009).
23. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 32(9), 1903-1910 (2007). (Pubitemid 47258518)
24. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum. Hered. 66, 87-98 (2008). (Pubitemid 351482562)
25. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
26. Gordon D, Finch SJ, Nothnagel M, Ott J. Power and sample size calculations for case-control genetic association tests when errors present: application to single nucleotide polymorphisms. Hum. Hered. 54, 22-33 (2002). (Pubitemid 35404246)
27. Douglas JA, Skol AD, Boehnke M. Probability of detection of genotyping errors and mutations as inheritance inconsistencies in nuclear-family data. Am. J. Hum. Genet. 70, 487-495 (2002). (Pubitemid 34112301)
28. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J. Psychiatr. Res. 42(2), 89-97 (2006).
29. Lin YC, Ellingwood VL, Bishop JR, Miller DD. The relationship between P-glycoprotein polymorphisms and response to olanzapine treatment in schizophrenia. Ther. Drug Monit. 28(5), 668-672 (2006). (Pubitemid 44564067)
30. Xing Q, Gao R, Li H et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7(7), 987-993 (2006). (Pubitemid 44644778)
31. Blanc O, Brousse G, Meary A, Leboyer M, Llorca PM. Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research. Fundam. Clin. Pharmacol. 24(2), 139-160 (2010).
32. Consoli G, Lastella M, Ciapparelli A et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 10(8), 1267-1276 (2009).
33. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindström L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J. Psychiatr. Res. 42(11), 884-893 (2008).
34. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25(11), 1391-1400 (2002). (Pubitemid 39663152)
35. Kuzman MR, Medved V, Bozina N, Grubišin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J. 11(1), 35-44 (2011).
36. Risselada AJ, Mulder H, Heerdink ER, Egberts TC. Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics 12(8), 1213-1227 (2011).
37. Jovanovic N, Bozina N, Lovric M, Medved V, Jakovljevic M, Peles AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur. J. Clin. Pharmacol. 66(11), 1109-1117 (2010).
38. Kastelic M, Koprivsek J, Plesnicar BK et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog. Neuropsychopharmacol. Biol. Psychiatr. 34(2), 387-392 (2010).
39. Sim K, Su A, Leong JY et al. High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study. Pharmacopsychiatry 37(4), 175-179 (2004). (Pubitemid 38916427)
40. Bakare MO. Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: is there a racial difference? BMC Res. Notes 12(1), 25 (2008).
41. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25(3), 197-220 (2000).
42. Lin KM, Poland RE, Nuccio I et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am. J. Psychiatry 146(10), 1307-1311 (1989). (Pubitemid 19258480)
43. Chang WH, Jann MW, Hwu HG et al. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese. J. Formos. Med. Assoc. 90(6), 572-578 (1991).
44. Yoo HD, Lee SN, Kang HA, Cho HY, Lee IK, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br. J. Pharmacol. 164(2b), 433-443 (2011).